Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

類似資料

• Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
  著者:: Jerevall, Piiha-Lotta, 等
  出版事項: (2010)
• HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease
  著者:: Habel, Laurel A, 等
  出版事項: (2013)
• Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
  著者:: Weiner, M., 等
  出版事項: (2013)
• Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
  著者:: Sgroi, Dennis C., 等
  出版事項: (2013)
• CYP2D6 and HOXB13/IL17BR: Combining inherited and tumor gene markers for prediction of tamoxifen resistance
  著者:: Goetz, Matthew P., 等
  出版事項: (2008)